News
Gilead Sciences, Kymera Therapeutics Set Cancer-Drug Collaboration
Gilead Sciences and Kymera Therapeutics have inked an exclusive cancer-drug option and licensing agreement potentially worth hundreds of million of dollars to Kymera. The companies on Wednesday said the deal is aimed at speeding the development and commercialization of a novel molecular-glue-degrader,
(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...
StockStory.org on MSN3d
5 Insightful Analyst Questions From Gilead Sciences’s Q1 Earnings CallGilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue ...
Gilead’s Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs. By Matthew Herper Jan. 22, 2024. Reprints. Yichuan Cao/Sipa USA via AP Images.
Besides Ascent-04, Gilead expects a readout by June from the phase 3 Ascent-03 trial pitting Trodelvy against chemo in first-line, PD-L1-negative metastatic TNBC.
In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the data was not as strong as hoped. At ...
Sept 7 (Reuters) - Gilead Sciences Inc's , opens new tab Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data released ...
Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...
The reversal of fortunes for Gilead Sciences' Trodelvy in an advanced form of breast cancer is complete, with an FDA approval unlocking what could be a sizeable new market for the TROP2-targeting ...
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer. Sep. 05, 2024 8:00 AM ET Gilead Sciences, Inc. (GILD) ...
Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1. Sponsored Bank ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback